基于人工智能的冠状动脉造影自动评估冠状动脉血流储备及不同血管扩张剂的影响
本研究为描述性研究,纳入21例前降支无阻塞性狭窄且伴慢血流的患者,利用人工智能方法从单体位冠状动脉造影自动计算体积血流量和冠状动脉血流储备(CFR)。结果显示CFR分析可行性达100%,尼可地尔注射后CFR显著高于腺苷注射后。
要点
- 基于人工智能的造影自动CFR评估可行性达100%(21/21)。
- 尼可地尔注射后CFR为2.29±0.29,腺苷注射后为2.15±0.27(校正后P=0.044)。
- 静息态2与静息态计算的CFR差异无统计学意义(P均>0.05)。
核心结论
- 初步证实基于单体位冠状动脉造影快速、自动评估冠状动脉体积血流量和CFR可行性高。
- 在冠状动脉慢血流患者中,尼可地尔注射后的CFR水平显著高于腺苷注射后的CFR水平。
研究设计与样本
- 描述性研究,筛选2022年6至9月于中国医学科学院阜外医院因疑似冠心病接受冠状动脉造影的患者。
- 纳入前降支无阻塞性狭窄(目测直径狭窄率<50%)且伴慢血流现象(TIMI血流分级≤2级)的患者,共21例,年龄(62±9)岁,女性5例(24%)。
主要发现
- 静息态体积血流量为(80.6±12.4)ml/min;硝酸甘油诱发充血态为(167.7±30.5)ml/min(校正后P<0.001);腺苷诱发充血态为(171.5±23.1)ml/min(校正后P<0.001)。
- 静息态2体积血流量为(83.8±15.6)ml/min,恢复至静息水平(校正后P=0.94);尼可地尔诱发充血态为(182.9±28.3)ml/min(校正后P<0.001)。
- 硝酸甘油、腺苷和尼可地尔注射后的CFR分别为2.09±0.29、2.15±0.27和2.29±0.29(P=0.034);以腺苷为参照,尼可地尔后CFR更高(校正后P=0.044)。
- 以静息态2体积血流量作为基线计算的CFR与利用静息态体积血流量计算的CFR差异均无统计学意义(P均>0.05)。
临床怎么用
- 基于单体位冠状动脉造影的人工智能方法可快速自动计算CFR,可行性高。
- 在冠状动脉慢血流患者中,尼可地尔诱发的CFR高于腺苷,选择血管扩张剂时需考虑此差异。
局限性
- 本研究为描述性研究,样本量较小(21例),结论需进一步验证。
- 仅纳入前降支无阻塞性狭窄且伴慢血流的患者,结果外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objectives: To explore the feasibility of a coronary angiography-based method developed with artificial intelligence which was able to automatically and quickly calculate coronary volumetric blood flow and coronary flow reserve (CFR), and explore the differences in CFR after injection of different vasodilators. Methods: This was a observational study screening patients with suspected coronary artery disease who underwent coronary angiography From June to September 2022 in Fuwai Hospital, Chinese Academy of Medical Sciences. Patients without obstructive coronary artery disease in the left anterior descending artery (<50% diameter stenosis by visual) and accompanied by coronary slow flow phenomenon (Thrombolysis in Myocardial Infarction flow grade ≤2) were enrolled. According to pre-specified coronary angiography acquisition protocol, one angiographic image in optimal projection was acquired for each of the following five states: baseline when none of the vasodilators was injected (resting state), intracoronary injection of 200 μg nitroglycerin (nitroglycerin-induced hyperemia), intracoronary injection of 100 μg adenosine (adenosine-induced hyperemia), 5 minutes after cessation of adenosine injection (resting state 2), and intracoronary injection of 4 mg nicorandil (nicorandil-induced hyperemia). Coronary volumetric blood flow and CFR were assessed in a fully automatic manner at an independent core laboratory. One-way repeated measures ANOVA was used to detect the differences in coronary volumetric blood flow at five states and the differences in CFR after injection of different vasodilators. Results: A total of 21 eligible patients were included. The age was (62±9) years, and 5 (24%) were female. Coronary volumetric blood flow at five states and CFR after injection of different vasodilators were successfully calculated in all patients, with a feasibility of 100% (21/21) for CFR. Resting coronary volumetric blood flow was (80.6±12.4) ml/min. Using this as a reference, the volumetric blood flow increased to (167.7±30.5) ml/min under nitroglycerin-induced hyperemia (adjusted P<0.001), and remained at (171.5±23.1) ml/min under adenosine-induced hyperemia (adjusted P<0.001). The volumetric blood flow under resting state 2 was (83.8±15.6) ml/min, returning to baseline level (adjusted P=0.94). Under nicorandil-induced hyperemia, the coronary volumetric blood flow increased again to (182.9±28.3) ml/min (adjusted P<0.001). CFR was 2.09±0.29, 2.15±0.27, and 2.29±0.29 after injection of nitroglycerin, adenosine, and nicorandil, respectively(P=0.034). Using CFR after adenosine injection as a reference, CFR after nicorandil injection was higher (adjusted P=0.044). Using the coronary volumetric blood flow under resting state 2 as the baseline flow for CFR calculation, there was no statistically significant difference compared to the CFR calculated using the volumetric blood flow under resting state (all P>0.05). Conclusions: Preliminary findings confirm the high feasibility of rapid, automated assessment of coronary volumetric blood flow and CFR from a single angiographic projection, as well as good reproducibility in calculating baseline volumetric blood flow. In patients with coronary slow flow, the CFR after nicorandil injection is significantly higher than that after adenosine injection. 目的: 初步探究利用人工智能技术开发的一项基于冠状动脉造影、自动快速计算冠状动脉体积血流量并评估冠状动脉血流储备(CFR)方法的可行性,并探究注射不同血管扩张剂后的CFR的差异。 方法: 本研究为描述性研究。筛选2022年6至9月于中国医学科学院阜外医院心内科因疑似冠心病接受冠状动脉造影检查的患者。纳入造影显示前降支无阻塞性冠状动脉狭窄(目测直径狭窄率<50%)且伴有慢血流现象(心肌梗死溶栓试验血流分级≤2级)的患者。根据预设的冠状动脉造影采集方案,获得最佳投照体位下5种状态冠状动脉造影图像各1幅:未注射任何血管扩张剂的基线状态(静息态),冠状动脉内注射200 μg硝酸甘油后(硝酸甘油诱发充血态),冠状动脉内注射100 μg腺苷后(腺苷诱发充血态),停止腺苷注射5 min后(静息态2),冠状动脉内注射4 mg尼可地尔后(尼可地尔诱发充血态)。于核心实验室进行全自动体积血流量和CFR评估。采用单因素ANOVA重复测量方差分析检测不同状态下体积血流量差异及不同药物注射后的CFR差异。 结果: 共纳入21例患者,年龄(62±9)岁,其中女性5例(24%)。均成功完成5种状态下体积血流量和CFR计算,CFR分析可行性达100%(21/21)。静息态体积血流量为(80.6±12.4)ml/min,以其为参照,硝酸甘油诱发充血态的体积血流量增加至(167.7±30.5)ml/min(校正后P<0.001),腺苷诱发充血态的体积血流量维持在(171.5±23.1)ml/min(校正后P<0.001),静息态2的体积血流量为(83.8±15.6)ml/min,恢复至静息水平(校正后P=0.94),尼可地尔诱发充血态的体积血流量再次升高至(182.9±28.3)ml/min(校正后P<0.001)。硝酸甘油、腺苷和尼可地尔注射后的CFR值分别为2.09±0.29、2.15±0.27和2.29±0.29(P=0.034)。以腺苷注射后的CFR作为参照,尼可地尔注射后的CFR水平更高(校正后P=0.044)。以静息态2的体积血流量作为基线流量参与CFR计算,与利用静息态体积血流量计算的CFR差异均无统计学意义(P均>0.05)。 结论: 初步证实基于单体位冠状动脉造影快速、自动评估冠状动脉体积血流量和CFR可行性高,且在计算基线血流量具有良好的可重复性。在冠状动脉慢血流患者中,尼可地尔注射后的CFR水平显著高于腺苷注射后的CFR水平。.
引用
- Zhang HL, Ding DX, Yang BT, et al. [Artificial intelligence-based automated assessment of coronary flow reserve from angiography and the impact of different vasodilators]. Zhonghua Xin Xue Guan Bing Za Zhi. 2025. PMID: 40389339. doi:10.3760/cma.j.cn112148-20250128-00075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。